Syncona
Syncona ({{lse|SYNC}}) is a large British closed-ended investment trust dedicated to life science investments. Co-founded as Syncona Partners in 2012 by current CEO Martin Murphy and the Wellcome Trust, before merging with the Battle Against Cancer Investment Trust ('BACIT') in December 2016 and listing publicly, the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.{{cite web|url=http://www.morningstar.co.uk/uk/news/AN_1482149035506195500/bacit-changes-name-to-syncona-after-investment-shift.aspx|title=BACIT Changes Name To Syncona After Investment Shift|date=19 December 2016|publisher=Morning Star|access-date=4 March 2017}} Its Chair is Melanie Gee.{{cite news|url=https://citywire.co.uk/investment-trust-insider/news/tigue-exiting-syncona-as-investment-banker-gee-joins-board/a1235416|title=Tigue exiting Syncona as investment banker Gee joins board|date=6 June 2019|newspaper=Citywire|access-date=5 August 2021}}
References
{{reflist}}
External links
- [http://www.synconaltd.com/ Official site]
{{FTSE 250 Index constituents}}
{{Authority control}}
Category:Investment trusts of the United Kingdom